Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)()

First-line therapy for higher-risk myelodysplastic syndromes (MDS) includes decitabine (DAC) or azacitidine (AZA). Variables have not identified differential response rates between these. We assessed the influence of patient sex on outcomes including overall survival (OS) in 642 patients with higher...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Lymphoma
Autori principali: DeZern, Amy E., Zeidan, Amer M., Barnard, John, Hand, Wesley, Al Ali, Najla, Brown, Francis, Zimmerman, Cassie, Roboz, Gail J., Garcia-Manero, Guillermo, Steensma, David P., Komrokji, Rami S., Sekeres, Mikkael A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5394924/
https://ncbi.nlm.nih.gov/pubmed/27774847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1246726
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi